News
GENFF
0.040
NaN%
--
Genflow Biosciences non-executive director Peter King-Lewis steps down from board
PUBT · 06/04 06:00
Genflow Biosciences publishes 2025 annual report
PUBT · 04/30 15:53
Genflow Biosciences announces annual report availability for year ended Dec. 31, 2025
PUBT · 04/30 13:07
Genflow expands confidentiality agreements with Tier-1 animal health companies for canine gene therapy
PUBT · 04/28 06:21
Genflow Biosciences enters LNP delivery technology collaboration with Acuitas Therapeutics
PUBT · 04/20 06:00
Genflow says SIRT6 variant patent publication targets frailty, sarcopenia muscle loss
PUBT · 04/13 06:17
Genflow Biosciences CEO Eric Leire and Chairman Gad Berdugo subscribe for new shares at 1.9p
Reuters · 03/05 12:06
Genflow Biosciences Reports Positive Interim Results for SIRT6 Gene Therapy in Aged Dogs
Reuters · 02/12 07:00
Genflow Biosciences Proposes Share Issuance and Pre-emption Rights Disapplication for Potential Equity Raise at Upcoming General Meeting
Reuters · 02/11 07:00
Genflow Biosciences Receives €4 Million Funding Approval from Wallonia Region
Reuters · 01/28 07:00
Genflow Biosciences Completes Dosing in Canine Gene Therapy Trial with No Adverse Events
Reuters · 12/16/2025 07:00
Genflow Biosciences to Attend J.P. Morgan Healthcare Conference
Reuters · 12/11/2025 07:01
Genflow Biosciences Announces Updated Total Issued Shares and Voting Rights
Reuters · 10/31/2025 07:00
Genflow Biosciences announces second European patent application
Seeking Alpha · 10/22/2025 06:57
Genflow Biosciences Publishes European Patent Application for SIRT6 Variant Targeting NASH
Reuters · 10/22/2025 06:00
Genflow Biosciences’ SIRT6 Variant Patent Claims Recognized as Patentable by European Patent Office
Reuters · 10/20/2025 06:00
Genflow Biosciences announces clinical trial update for SIRT6 gene therapy in aging dogs
Reuters · 10/10/2025 06:00
Genflow Biosciences PLC Announces Update on Animal Health Program
Barchart · 10/09/2025 21:00
Genflow Biosciences plc CEO Eric Leire Subscribes for 40 Million New Ordinary Shares in Latest Commercial Paper Deal
Reuters · 10/09/2025 06:17
Genflow Biosciences Secures Wallonia Region Grant to Advance SIRT6 Gene Therapy Program GF-1002 Toward Clinical Development
Reuters · 09/30/2025 06:00
More
Webull provides a variety of real-time GENFF stock news. You can receive the latest news about Genflow Biosciences through multiple platforms. This information may help you make smarter investment decisions.
About GENFF
Genflow Biosciences Plc is a United Kingdom-based biotechnology company. The Company is engaged in developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases, which is done through therapeutics targeting aging in humans by using adeno-associated virus (AAV) vectors to deliver copies of the Sirtuin-6 (SIRT6) gene variant that is found in centenarians into cells. The Company's product pipeline includes GF-1002, GF-1003, GF-1004, GF-1005 and GF-1006. GF-4001. GF-1002 is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. GF-1004 is a non-human version of GF-1002 anti-ageing gene therapy developed for veterinary use (dogs). GF-1003 is a formulation of an adeno-associated viral vector-based gene therapy. The Company has operations in the United Kingdom and Belgium.